Company news
Valeo Pharma Inc. (OTC:VPHIF) news
Valeo Pharma Inc. news releases on 6ix. Latest, Jun 14, 2022: VALEO PHARMA REPORTS ITS SECOND QUARTER 2022 RESULTS AND HIGHLIGHTS
Press releases — page 2
VALEO PHARMA REPORTS ITS SECOND QUARTER 2022 RESULTS AND HIGHLIGHTS
June 14, 2022
VALEO PHARMA TO HOST SECOND QUARTER 2022 RESULTS CONFERENCE CALL / WEBCAST
June 8, 2022
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS, APPOINTMENTS AND OPTIONS AND RSU GRANTS
April 28, 2022
VALEO PHARMA TO PRESENT AT THE 2022 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE
April 25, 2022
VALEO PHARMA ANNOUNCES LISTING OF CONVERTIBLE DEBENTURES ON TSX
April 19, 2022
VALEO PHARMA ANNOUNCES LISTING TO THE TORONTO STOCK EXCHANGE
March 28, 2022
VALEO PHARMA REPORTS ITS FIRST QUARTER 2022 RESULTS AND HIGHLIGHTS
March 24, 2022
VALEO PHARMA SECURES ADDITIONAL PUBLIC REIMBURSEMENT FOR REDESCA™, ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER®
March 22, 2022
VALEO PHARMA TO HOST FIRST QUARTER 2022 RESULTS CONFERENCE CALL / WEBCAST AND ATTEND THE 8TH ANNUAL ALPHANORTH CAPITAL CONFERENCE
March 17, 2022
VALEO PHARMA REPORTS RECORD ANNUAL REVENUES FOR FISCAL 2021
February 28, 2022
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN ONTARIO, MANITOBA AND NEW BRUNSWICK
February 24, 2022
VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2021 RESULTS CONFERENCE CALL / WEBCAST
February 21, 2022
VALEO PHARMA'S HESPERCO™ NOW AVAILABLE AT LOBLAWS, HESPERIDIN COVID-19 CLINICAL TRIAL RESULTS SUBMITTED FOR PUBLICATION
January 5, 2022
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN QUEBEC AND NOVA SCOTIA
December 15, 2021
VALEO PHARMA CLOSES PREVIOUSLY ANNOUNCED UPSIZED $15 MILLION BOUGHT DEAL PRIVATE PLACEMENT AND CONCURRENT $10 MILLION PRIVATE PLACEMENT FROM INVESTISSEMENT QUEBEC
December 9, 2021
Valeo Pharma Announces Upsize of Previously Announced Bought Deal Private Placement of Convertible Debentures to $15 Million With Concurrent $10 Million Private Placement From Investissement Quebec
November 24, 2021
Valeo Pharma Announces $10 Million Bought Deal Private Placement of Convertible Debentures With Concurrent $10 Million Private Placement From Investissement Quebec
November 24, 2021
Valeo Pharma Obtains Public Reimbursement for Redesca™ and Redesca Hp™ in Quebec
November 15, 2021
Valeo Pharma Obtains Public Reimbursement For Enerzair® Breezhaler® and Atectura® Breezhaler® In Alberta
November 3, 2021
Valeo Pharma Obtains Listings for Redesca in 700 Hospitals and Healthcare Facilities Across Canada
October 13, 2021
Valeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Enerzair® Breezhaler® and Atectura® Breezhaler®
October 5, 2021
Valeo Pharma Announces Record Revenues and Gross Margins for its Third Quarter 2021
September 22, 2021
Valeo Pharma To Report Third Quarter 2021 Results and Hold Investors Conference Call / Webcast
September 16, 2021
Valeo Pharma Reports on Launch of New Corporate Structure
August 16, 2021
Valeo Pharma Announces Additional Provincial Reimbursement Coverage for Redesca™ and Redesca HP™
July 13, 2021
Valeo Pharma Reports its Second Quarter 2021 Results and Highlights
June 29, 2021
Valeo Pharma Closes $11.5 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
June 29, 2021
Valeo Pharma to Report Second Quarter 2021 Results and Hold Investors Conference Call / Webcast
June 23, 2021
Valeo Pharma Announces Commercial Launch of Enerzair® Breezhaler® and Atectura® Breezhaler®
June 22, 2021
Valeo Pharma Provides Update on Private Payer Reimbursement for Enerzair® Breezhaler® and Atectura® Breezhaler®
June 1, 2021
Valeo Pharma Projecting Record Revenues for Second Quarter 2021
May 26, 2021
Valeo Pharma Joins Innovative Medecines Canada
May 17, 2021
Valeo Pharma Announces Voting Results of its 2021 Annual General and Special Meeting of Shareholders
April 29, 2021
Valeo Pharma's Redesca® and Redesca HP® to Be Covered Under the Ontario Public Drug Benefit Program
April 28, 2021
Valeo Pharma Upsizes And Closes $6.6 Million Non-Brokered Private Placement
April 27, 2021
Valeo Pharma Announces Commercial Launch of Redesca™ and Redesca HP™
April 15, 2021
Valeo Pharma Announces $4.0 Million Non-Brokered Private Placement of Non-Convertible Debentures
April 14, 2021
Valeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Redesca® and Redesca HP®
April 6, 2021
Valeo Pharma Inc - Ordinary Shares - Class A to Host Earnings Call
March 31, 2021
Valeo Pharma Reports its First Quarter 2021 Results and Highlights
March 31, 2021
Valeo Pharma Inc. Enters into an Agreement for Enerzair® Breezhaler® and Atectura® Breezhaler® in Canada
March 29, 2021
Valeo Pharma to Report First Quarter 2021 Results and Hold Investors Conference Call / Webcast
March 26, 2021
Valeo Pharma Reports its 2020 Fourth Quarter and Year-End Results and Highlights
February 24, 2021
Valeo Pharma to Report Fourth Quarter and 2020 Year-End Results and Hold Investors Conference Call / Webcast
February 19, 2021
Valeo Pharma's Hesperco™ Capsules at the Core of Montreal Heart Institute's Hesperidin Coronavirus Clinical Trial
February 17, 2021
An Aging Population is Increasing the Need for Novel Treatments
February 3, 2021
Valeo Pharma's Redesca™ Receives Positive Recommendation for Public Reimbursement in Quebec
January 25, 2021
Valeo Pharma Announces Major Addition to its Senior Management Team
January 18, 2021
Valeo Pharma Highlights MDBriefCase Newsletter Comparing Hesperidin and Vitamin C for COVID-19
January 12, 2021
Valeo Pharma Announces DTC Eligibility for the Trading of Its Shares on the US OTCQB Market
December 29, 2020